Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Price
CTNMStock
$17.05+67.30%52W
Market Cap$641.44M
P/E—
PEG Ratio—
Div yield—
Beta-0.03
CTNM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-1.98%
Price vs S&P 500 (4W)14.39%
VGM Score79.84
CTNM Earnings Surprise History
Q2 25-0.62est. -0.41
Q3 25-0.45est. -0.46
Q4 25-0.49est. -0.39
Q1 26-0.39est. -0.53
Q2 26-0.40est. -0.45
CTNM Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.31
4.31
4.31
4.29
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTNMContineum Therapeutics, Inc. Class A Common Stock | — | — | B | $17.05 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for serious diseases with high unmet need. The company's pipeline includes PIPE-791, a brain-penetrant LPA1 receptor inhibitor in development for idiopathic pulmonary fibrosis, and PIPE-307, a muscarinic M1 receptor inhibitor for depression and relapsing-remitting multiple sclerosis.